July 17, 2020 Impact: Moderate ADC Therapeutics has dosed the first patient in the pivotal phase 2 portion of its phase 1/2 LOTIS 3 trial (NCT03684694) of loncastuximab tesirine plus ibrutinib in R/R DLBCL or MCL (Mantle Cell Lymphoma).
…
July 8, 2020 Impact: High FDA has issued a CRL (Complete Response Letter) in response to the sBLA for the combination of Keytruda/Lenvima (pembrolizumab/lenvatinib) to treat first-line (1L) unresectable HCC (hepatocellular carcinoma).…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-07-21 15:16:052020-07-23 14:17:01HCC Updates: Keytruda/Lenvima Receives Unexpected FDA CRL in 1L HCC & BeiGene Submits sNDA for Tislelizumab in China for 2L+ HCC
July 2, 2020 Impact: High Regeneron and Sanofi have announced that a Regeneron-led phase 3 U.S. trial of Kevzara (sarilumab) in patients with COVID-19 failed to meet its primary or key secondary endpoints and has been stopped early. The…
June 23, 2020 Impact: Moderate Researchers at the University of Oxford reported results from a randomized study of patients with severe cases of COVID-19, with either oral or intravenous administration of the widely available steroid…
June 23, 2020 Impact: High Inventiva has released topline results from the phase 2b NATIVE trial of its pan-PPAR agonist, lanifibranor, for the treatment of NASH.
The primary endpoint of the trial, the Steatosis Activity Fibrosis…
June 2, 2020 Impact: High Gilead and Galapagos have announced positive topline results from the phase 2b/3 randomized, double-blind, placebo-controlled of the oral selective JAK1 inhibitor given once-daily. The results were particularly…
https://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.png00old adminhttps://inthought.com/wp-content/uploads/2019/03/inThought-Logo-Transparent-3.7.pngold admin2020-06-02 21:02:502020-06-02 21:02:50Positive SELECTION Data for Filgotinib in UC: Only the 200mg Dose Achieves Induction Primary Endpoint